Navigation Links
Cempra Provides Guidance on the Clinical Program Required for Regulatory Approval for Solithromycin for Community-Acquired Bacterial Pneumonia (CABP)
Date:6/13/2013

the Generating Antibiotic Incentives Now (GAIN) Act. The pathogens proposed for eligibility include Campylobacter, Enterococcus, Neisseria gonorrhoeae, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, the Mycobacterium tuberculosis complex of species and non-tuberculous Mycobacteria species. Solithromycin has demonstrated activity against all of these pathogens.  There can be no assurances that the FDA proposal, which is subject to a public comment period, will become a final rule or that, if passed, the final rule will include any or all of the above-mentioned pathogens.

About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases.  Cempra's two lead product candidates are currently in advanced clinical development.  Solithromycin (CEM-101) is in a Phase 3 clinical trial for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan.  TAKSTA™ (CEM-102) is Cempra's second product candidate currently in a Phase 2 clinical trial for prosthetic joint infections.  Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to use its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and unce
'/>"/>

SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cempra Presents Post-Phase 2 Analysis of Solithromycins Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)
2. Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
3. Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. The Hemostemix Group of Companies Provides Corporate Strategy Update
5. Study led by GW professor provides better understanding of waters freezing behavior at nanoscale
6. Yongye International Provides Update on Status of Proposed Go Private Offer
7. Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
8. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials
9. Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update
10. Adamis Pharmaceuticals CEO Provides Update for Shareholders
11. Cellular Biomedicine Group Provides Update and 2013 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 High performance computing (HPC) ... most complete climate and Earth system model to ... issues. , Eight national laboratories, including Lawrence ... Center for Atmospheric Research, four academic institutions and ... participating national laboratories include Argonne, Brookhaven, Lawrence Berkeley, ...
(Date:8/20/2014)... 20, 2014 The 6th Annual ... held on October 29-30 in San Francisco, CA. This ... and government researchers and clinicians focused on addressing and ... , In the twelve years since the sequencing of ... been introduced with pharmacogenetic information in the label and ...
(Date:8/20/2014)... ear could improve the health of your heart, researchers ... Leeds used a standard TENS machine like those designed ... the tragus, the small raised flap at the front ... canal. , The stimulation changed the influence of the ... signals that can drive failing hearts too hard. , ...
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
Breaking Biology Technology:New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 36th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... Systems, Inc. (OTC Bulletin Board: OMCM) announced that it ... for the purpose of resolving the patent infringement lawsuit ... into a licensing arrangement with DataSci. OmniComm CEO ... come to an agreement in this matter. This ...
... ATLANTA, April 15 CryoLife, Inc. (NYSE: CRY ... processing company, announced today that 2009 first quarter financial results ... that day, the Company will hold a teleconference call and ... results, followed by a question and answer session hosted by ...
... DCGN ) today announced that in order to ... under consideration, it has,elected to utilize a 30-day grace ... outstanding 3.5% Senior Convertible Notes due 2011. , ... deCODE is a biopharmaceutical company developing drugs and ...
Cached Biology Technology:OmniComm Systems Announces Settlement of Patent Litigation With DataSci, LLC 2CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results 2deCODE to Utilize Grace Period for Interest Payment on Senior Convertible Notes 2
(Date:8/20/2014)... approximately 3 million infants, a team of scientists across ... Massachusetts Medical School, have shown that newborn screening for ... public health newborn screening programs. Data from 11 newborn ... the Journal of the American Medical Association ... newborns is higher than previously thought and believed to ...
(Date:8/20/2014)... suffered concussions ready to return to action? A new ... athletes who head back on the field with medical ... their abilities to simultaneously walk and do simple mental ... their balance and/or altered walking speed, was found in ... returned to activity in less than a month. Seven ...
(Date:8/20/2014)... bags could one day be made out of cocoa, ... now reporting. The novel process they developed and their ... agricultural and plastic waste problems, appear in the ACS ... Bayer and colleagues at the Italian Institute of Technology ... 2012, its production reached 288 million tons worldwide, but ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... (OTC Bulletin Board: CICI) Communication Intelligence Corporation ... supplier of electronic signature solutions for business process ... leader** in biometric signature verification announced today its ... year ended December 31, 2008.Total revenues for the ...
... ILInsects such as honeybees and bumble bees are predictable in ... one flower to an adjacent cluster of flowers in the ... direct affect on their ability to hunt for pollen and ... pollen moves from one plant to another. The study of ...
... National Institute of Child Health and Development (NICHD) of the ... Medicine of Yeshiva University a $7.5 million grant to establish ... (SCCPIR).One of only 13 such centers in the country and ... will focus on a wide range of diseases of the ...
Cached Biology News:Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 2Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 3Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 4Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 5Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 6Flight of the bumble (and honey) bee 2NIH funds research center for women's reproductive health at Einstein 2NIH funds research center for women's reproductive health at Einstein 3
ANTI-HUMAN CYTOKINES, GROWTH FACTORS (polyclonal rabbit (or goat) antibodies) Human TARC - Biotin...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Chicken polyclonal to Thioredoxin domain containing 9 ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez Gene ID: 10190 Swiss Protein ID: O14530...
Biology Products: